What type of study is this?

October 9, 2025JCO Oncology Practice

Intensity of end-of-life cancer (EOL) care in Medicare Advantage (MA) vs Traditional Medicare (TM).

View Full Paper

Ask AI

Bookmark

Authors

JXJenny XiangUniversity of Colorado Cancer Center JNJiangong NiuThe University of Texas MD Anderson Cancer Center KAKerin B. AdelsonThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Analysis reveals differences in end-of-life care metrics for Medicare Advantage versus traditional Medicare enrollees, suggesting implications for treatment quality.

Key Points

MA enrollees had lower odds of all end-of-life outcomes compared to TM enrollees, indicating potential differences in cancer management practices.
56.1% of TM enrollees and 60.5% of MA enrollees received systemic anticancer therapy in their last year of life, demonstrating treatment disparities.
Multivariable logistic regression was used to compare end-of-life outcomes, adjusting for various patient demographics and comorbidities.
Results highlight that despite lower intensive care use in MA, it may not reflect superior cancer care quality, especially among patients receiving therapy.

Cite This Study

Xiang et al. (2025) studied this question.

synapsesocial.com/papers/68e70dab90569dd607ee5f97 https://doi.org/10.1200/op.2025.21.10_suppl.309

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals differences in end-of-life care metrics for Medicare Advantage versus traditional Medicare enrollees, suggesting implications for treatment quality.

Intensity of end-of-life cancer (EOL) care in Medicare Advantage (MA) vs Traditional Medicare (TM).

Discussion

Member takes

Implication

Key Points

Cite This Study

Intensity of end-of-life cancer (EOL) care in Medicare Advantage (MA) vs Traditional Medicare (TM).

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider